Phase 3 Clinical Trials With Primary Completion Dates in August 2023
This is a list of Phase 3 trials with primary completion dates in August 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ACAD||ACADIA Pharmaceuticals Inc.||2023-08-01||Phase 3||NCT03623321||Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease|
|ALVO||Alvotech||2023-08-01||Phase 3||NCT05155293||Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)|
|BVNRY||Bavarian Nordic A/S||2023-08-01||Phase 3||NCT02977715||IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo|
|CBAY||CymaBay Therapeutics, Inc.||2023-08-01||Phase 3||NCT04620733||RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)|
|DNLI||Denali Therapeutics Inc.||2023-08-01||Phase 3||NCT05418673||A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale|
|ITCI||Intra-Cellular Therapies, Inc.||2023-08-01||Phase 3||NCT04985942||Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder|
|LIAN||LianBio||2023-08-01||Phase 3||NCT05629390||Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study|
|MNKD||MannKind Corporation||2023-08-01||Phase 3||NCT04974528||Afrezza® INHALE-1 Study in Pediatrics|
|NAVB||Navidea Biopharmaceuticals, Inc.||2023-08-01||Phase 3||NCT05246280||Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA|
|NBIX||Neurocrine Biosciences, Inc.||2023-08-01||Phase 3||NCT04490915||Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia|
|SLNO||Soleno Therapeutics, Inc.||2023-08-01||Phase 3||NCT03714373||Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period|
|TVTX||Travere Therapeutics, Inc.||2023-08-01||Phase 3||NCT03762850||A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy|